Armata Pharmaceuticals has received FDA Breakthrough Therapy designation for AP-SA02, an intravenous multi-phage therapy designed to combat complicated Staphylococcus aureus bacteremia, including anti

Key Points Armata Pharmaceuticals received an additional $3.7 million in non-dilutive funding from the U.S. Department of War for its AP-SA02 Phase 3 clini

Armata Pharmaceuticals has announced the acquisition of an additional $3.7 million in funding from the U.S. Department of War for its Phase 3 development of AP-SA02, targeting antibiotic-resistant infections.

Click to view the official SEC document.

Armata Pharmaceuticals is set to unveil findings at ISSSI 2026 that reveal how genetic diversity in AP-SA02 improves its effectiveness against Staphylococcus aureus.

FDA awards Breakthrough Therapy designation to Armata’s AP-SA02 for adjunct treatment of complicated staph bacteremia, including MRSA.

Click to view the official SEC document.

Armata Pharmaceuticals celebrates a significant milestone with the FDA granting Breakthrough Therapy designation to AP-SA02, revolutionizing bacterial infection treatment.

Reported Monday, Sep 14 - 7:01am EDT (TheFly subscription required to read more.)

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Armata Pharmaceuticals has revealed its second quarter 2026 financial performance and pivotal corporate developments, signaling significant advancement in bacterial infection treatment.

Armata Pharmaceuticals (NYSE American: ARMP) reported second quarter 2026 results and detailed progress on its lead phage therapeutic AP-SA02 for complicated Staphylococcus aureus bacteremia. The company submitted a finalized Phase 3 superiority trial protocol to the FDA, completed key manufacturing assays and engineering runs, and obtained FDA Fast Track designation plus an Agreed Initial Pediatric Study Plan. Armata received an additional $2.5 million in non-dilutive funding from the U.S. Department of War, bringing that award’s total to $28.7 million. For Q2 2026, grant and award revenue was $2.5 million, operating loss was $10.3 million, and net income was $74.1 million driven by a $91.0 million non-cash gain on its Convertible Loan. Cash and cash equivalents rose to $24.0 million at June 30, 2026, following a $25.0 million term loan and at-the-market equity issuance.

Armata Pharmaceuticals hat im Januar 2026 angekündigt, seinen Phagentherapie-Kandidaten AP-SA02 in Phase 3 zu führen. Es ist das erste Mal weltweit, dass eine Phagentherapie diese Stufe klinischer Forschung erreicht. Ziel ist eine Behandlung für gefä

Armata Pharmaceuticals is advancing a novel bacteriophage therapeutic, AP-SA02, towards a Phase 3 clinical trial to treat severe antibiotic-resistant bacterial infections. This investigational therapy

Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.

Armata Pharmaceuticals (NYSE: ARMP) is lining up its lead bacteriophage candidate AP‑SA02 for a pivotal Phase 3 trial, after checking off a series of clinical

Armata Pharmaceuticals has announced major progress in its Phase 3 preparations for AP-SA02, a treatment for S. aureus bacteremia, following key regulatory submissions.

Click to view the official SEC document.

Reported Monday, Jul 20 - 7:06am EDT (TheFly subscription required to read more.)

FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step Phase 3 superiority study remains on track to initiate in the...

Armata Pharmaceuticals (NYSE American: ARMP) reported multiple milestones supporting the planned Phase 3 superiority study of AP-SA02, its intravenous multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia caused by MSSA or MRSA. The company submitted the complete Phase 3 protocol and comprehensive responses to all U.S. FDA comments from the End-of-Phase 2 meeting, covering clinical, Chemistry, Manufacturing and Controls, and regulatory topics. Armata also completed four engineering runs of AP-SA02 at its in-house cGMP facility in Los Angeles, with production of Phase 3 clinical trial material as the next step. In June 2026, Armata received an additional $2.5 million continuation award from the U.S. Department of Defense, bringing total funding under this award to $28.7 million to support Phase 3 preparations. The pivotal trial remains on track to initiate in the second half of 2026 and is intended to support a future BLA. The company promoted David House to Chief Financial Officer to support late-stage development and strategy execution.

Click to view the official SEC document.

Armata Pharmaceuticals has achieved a significant regulatory milestone with FDA approval of a pediatric study plan for AP-SA02 to treat complicated Staphylococcus aureus bacteremia in children.